•   
  •   
  •   

Canada Not available in Canada: A look at COVID-19 vaccine tech from China, India and Cuba

12:41  04 may  2021
12:41  04 may  2021 Source:   cbc.ca

COVID protocol-related absences: 04/25

  COVID protocol-related absences: 04/25 Each day, the NHL will publicly release the list of players that are unavailable to their respective teams due to being in COVID-19 Protocol. Here is today’s list: Calgary – Josh Leivo Colorado – Joonas Donskoi, Mikko Rantanen New Jersey – P.K.Calgary – Josh Leivo

a person in a blue uniform holding a gun: A healthcare worker prepares a dose of China's Sinovac Biotech vaccine for the coronavirus disease (COVID-19) at a drive-thru vaccination station, as a mass vaccination program continues in Jakarta, Indonesia, April 30, 2021. It's an inactivated vaccine being used in countries around the world, but not in Canada. © Ajeng Dinar Ulfiana/Reuters A healthcare worker prepares a dose of China's Sinovac Biotech vaccine for the coronavirus disease (COVID-19) at a drive-thru vaccination station, as a mass vaccination program continues in Jakarta, Indonesia, April 30, 2021. It's an inactivated vaccine being used in countries around the world, but not in Canada.

COVID-19 vaccines developed in China are already being used in several countries around the world. And some developed in India, Kazakhstan and Cuba have been in use domestically for their own populations even before completion of Phase 3 trials.

Vaccines being made in some of those countries (including the Serum Institute of India's Covishield version of the AstraZeneca vaccine) use the viral vector technology or mRNA technologies used to inoculate Canadians. But other vaccines developed domestically are quite different.

The Latest: Merck in deal with India on antiviral drug

  The Latest: Merck in deal with India on antiviral drug KENILWORTH, New Jersey — Merck announced a deal with five makers of generic drugs in India to produce molnupiravir, an experimental antiviral similar to the COVID-19 medicine remdesivir but in a more convenient pill form. Late-stage testing of the drug just started in the United States, and it’s unclear when the medicine might be used in India or elsewhere. A mid-stage study gave encouraging results, suggesting the drug quickly reduced virus levels when used early after infection. Remdesivir is widely used for certain hospitalized patients but must be given as an infusion, which limits its use.

Here's a closer look at two kinds of COVID-19 vaccines —inactivated and conjugate protein vaccines — developed in middle-income countries and not available in Canada.

Inactivated Vaccines

Vaccines of this kind have been developed by , headquartered in Shanghai China and , in Beijing, China, in Hydrabad, India and in Zhambyl, Kazakhstan.

This is a tried and true strategy used in many vaccines against diseases including hepatitis A and rabies. It involves growing up whole viruses — in this case, SARS-CoV-2, the virus that causes COVID-19 — and then inactivating them so they can't cause infection. For SARS-Cov-2, the inactivation is typically done with a chemical called beta-propiolactone. The virus is injected with an adjuvant, typically aluminum-based, to boost immune response. Unlike mRNA vaccines, these vaccines also don't require ultra-cold storage. A regular fridge will do.

COVID protocol-related absences: 04/27/21

  COVID protocol-related absences: 04/27/21 Each day, the NHL will publicly release the list of players that are unavailable to their respective teams due to being in COVID-19 Protocol. Here is today’s list: Anaheim – Adam Henrique Calgary – Josh Leivo Montreal – TBA New Jersey – P.K.Anaheim – Adam Henrique

diagram: How inactivated vaccines for COVID-19 are made and how they work. © CBC News How inactivated vaccines for COVID-19 are made and how they work.

The frontrunners are the Chinese inactivated vaccines, already approved for emergency use and being used in mass vaccination in dozens of countries around the world on nearly all continents. They were being evaluated by the World Health Organization for Emergency Use Listing this spring. Bharat Biotch released interim Phase 3 results for its Covaxin vaccine in March and April, and the vaccine has been in use in its home country since January, when it was approved for emergency use there. Similarly, the Research Institute for Biological Safety Problems rolled out its vaccine QazVac on April 23, about halfway through the completion of its Phase 3 trials.

None have released final results of their Phase 3 trials, but all results so far surpass the World Health Organization's minimum of 50 per cent efficacy:

Vaccine envy: Why can't Canada make COVID-19 doses at home?

  Vaccine envy: Why can't Canada make COVID-19 doses at home? Canada's domestic vaccine manufacturing capability has been hollowed out, leaving the country entirely dependent on foreign sources for COVID-19 vaccines. What happened?Canada's domestic vaccine manufacturing capability has been hollowed out, leaving the country entirely dependent on foreign sources for the doses that promise an eventual return to normal life.

  • Sinopharm has said its vaccine has a 79 per cent efficacy, and the U.A.E. said its trials of the vaccine showed it had 86 per cent efficacy.

  • Bharat Biotech has reported interim efficacy as 79 to 81 per cent.

a group of people standing in front of a crowd: People wait to receive Bharat Biotech's COVAXIN vaccine for COVID-19 at an indoor stadium in Gauhati, India, Thursday, April 22, 2021. The inactivated vaccine has been in use in India since January. It released interim results of Phase 3 trials in March and April. © Anupam Nath/The Associated Press People wait to receive Bharat Biotech's COVAXIN vaccine for COVID-19 at an indoor stadium in Gauhati, India, Thursday, April 22, 2021. The inactivated vaccine has been in use in India since January. It released interim results of Phase 3 trials in March and April.

Video: Weighing the benefits against the risks of the AstraZeneca vaccine (cbc.ca)

Colin Funk, an adjunct professor with Queen's University in Kingston, Ont., and biomedical consultant with Vancouver-based Novateur Ventures co-authored a paper in the journal Viruses earlier this year comparing all the frontrunning vaccines around the world, including Sinovac's and Sinopharm's.

"They are working, but not as well for sure as the mRNA vaccines," he said. Pfizer and Moderna both reported efficacy of more than 94 per cent. Funk said  it's been difficult to get reliable information as the Chinese companies haven't published their final results. Since they're in use in many countries, though, he added that it should become clear in a few months how well they work.

Desperate families in India turn to social media seeking help for loved ones with COVID-19

  Desperate families in India turn to social media seeking help for loved ones with COVID-19 Prince William and Duchess Catherine are today celebrating their 10th Wedding Anniversary and we are looking back at some of their best moments.

While officially these vaccines' efficacy is lower, they do have an advantage — fewer side effects, especially fever. That's the side effect which can cause the most concern, said Craig LaFerriere, head of vaccine development at Novateur Ventures, who co-authored the paper with Funk. Fever appear in less than two per cent of those vaccinated with inactivated vaccines, compared to 15 per cent of those who receive mRNA and viral vector vaccines.

Conjugate vaccines

There are at least two Cuban vaccines of this type, billed as the only COVID-19 vaccines of their kind: Soberana 02 (the name means "sovereignty"), made by the Finlay Institute of Vaccines in Havana; and Mambisa, developed by the Center for Genetic Engineering and Biotechnology (CIGB).

Conjugate protein vaccines are a special type of protein subunit vaccine made with an antigen (a substance that can cause an immune response) from the target disease bound to a strong antigen from another disease to boost the immune response. A common one that you have probably been vaccinated with is Haemophilus influenza type b (Hib), a standard childhood vaccine against meningitis, which includes the sugar coating or polysaccharide from Hib linked to a diphtheria, meningococcal or tetanus protein. In the case of Soberana 02, the receptor binding domain from the spike protein of the SARS-CoV-2 virus that causes COVID-19 is bound to a tetanus toxoid, Cuban doctors reported in global healthcare journal BMJ . A second Cuban conjugate vaccine, Mambisa, contains the same coronavirus protein and a Hepatitis B protein. Protein-based vaccines can be stored in a regular fridge.

Canada is holding back its 1-shot J&J COVID-19 vaccine. Here’s what you need to know

  Canada is holding back its 1-shot J&J COVID-19 vaccine. Here’s what you need to know Health Canada on Friday said that they were holding back 300,000 doses of the one-shot J&J vaccine — mere days before they were meant to be deployed.On Friday, Health Canada announced it is holding back the J&J vaccine, a one-shot dose that experts and health officials touted as crucial in stemming the spread of the virus amid a devastating third wave of the pandemic, after it was revealed that parts of the batch were made in the same Baltimore plant where millions of other doses meant for the U.S. market had spoiled.

diagram: How conjugate vaccines for COVID-19 work and how they're made. © CBC News How conjugate vaccines for COVID-19 work and how they're made.

Soberana 02 is one of two Cuban vaccines listed by the World Health Organization as being in late-stage Phase 3 clinical trials right now (The other is Abdala a traditional protein subunit vaccine with an aluminum-based adjuvant). It's already being used in Havana as part of an "interventional study," that doesn't involve double-blind testing or placebos. Mambisa, designed to be administered as a nasal spray instead of an injection, started Phase 1 trials in March.

We don't know. Data from the trials have not been released or published, although there are some preclinical results published on a preprint server. Vicente Vérez Bencomo, director-general of the Finlay Institute told the journal Nature in April that Phase 1 and 2 trials of Soberana 02 showed 80 per cent of people who received two doses had an antibody response. Some were given an additional booster in the form of Soberana Plus, a version of the vaccine targeted at those who have previously had COVID-19 and 100 per cent of them showed an antibody response, he added.

a group of people standing in a room: Healthcare workers run testing on volunteers of the Soberana-02 COVID-19 vaccine as part of Phase 3 of one of two experimental Cuban vaccines in Havana Wednesday, March 24, 2021. © Ramon Espinosa/Pool Photo/The Associated Press Healthcare workers run testing on volunteers of the Soberana-02 COVID-19 vaccine as part of Phase 3 of one of two experimental Cuban vaccines in Havana Wednesday, March 24, 2021.

But Cuba has successfully made a Hib vaccine based on this technology, and has decades of experience with it, said Helen Yaffe, a lecturer in economic and social history at the University of Glasgow who has studied Cuba's state-owned biotechnology industry. "I think most of the world takes Cuba's biotech products very seriously," she said. Funk of Queen's University agreed that Cuba does very good research, and said of Soberana 02, "For sure I think that would be a candidate that might advance and could be used in certain countries around the world," Funk said. "We'll just have to see."

Future of AstraZeneca COVID-19 vaccine in question in Canada over blood clots, supply issues .
The future use of the AstraZeneca-Oxford COVID-19 vaccine in Canada is now in question due to concerns over the increased risk of rare but severe blood clots connected to the shot, an unpredictable future supply and a significant amount of alternative vaccines.Alberta was the first province to confirm it would stop administering first doses of the AstraZeneca vaccine, citing a scarcity of supply. The province will instead prioritize mRNA vaccines like Pfizer-BioNTech and Moderna while reserving existing AstraZeneca for second doses.

usr: 1
This is interesting!